Cotellic cobimetinib regulatory update

EMA’s CHMP recommended approval of Cotellic cobimetinib in combination with Zelboraf vemurafenib to treat adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. The companies expect a decision by year end. ...